| Description | Doxycycline monohydrate is an inhibitor of metalloproteinase (MMP) |
| In vivo | Doxycycline treatment inhibits the activity of tissue MMP and attenuates the decrease in the collagen content in aortas of mice haploinsufficient for collagen III, as well as prevents the development of stress-induced vessel pathology.?Doxycycline merits clinical testing as a treatment for vEDS[1]. |
| Synonyms | 水合强力霉素, 强力霉素一水物 |
| molecular weight | 462.4 |
| Molecular formula | C22H26N2O9 |
| CAS | 17086-28-1 |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (108.13 mM) |
| References | 1. Briest W , Cooper T K , Tae H J , et al. Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome[J]. Journal of Pharmacology & Experimental Therapeutics, 2011, 337(3):621-627. 2. Trajano V C C , Costa K J R , Lanza C R M , et al. Osteogenic activity of cyclodextrin-encapsulated doxycycline in a calcium phosphate PCL and PLGA composite[J]. Materials science & engineering, 2016, 64(jul.):370-375. |